We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Device Detects Viruses Like COVID-19 in the Body as Fast as Rapid Tests With 95% Accuracy

By LabMedica International staff writers
Posted on 30 Nov 2021
Print article
Image: UCF’s Optical Chip for Virus Detection (Photo courtesy of University of Central Florida)
Image: UCF’s Optical Chip for Virus Detection (Photo courtesy of University of Central Florida)

Researchers have developed a device that detects viruses like COVID-19 in the body as fast as and more accurately than current, commonly used rapid detection tests.

The optical sensor developed by researchers at the University of Central Florida (UCF; Orlando, FL, USA) uses nanotechnology to accurately identify viruses in seconds from blood samples. Researchers say the device can tell with 95% accuracy if someone has a virus, a significant improvement over current rapid tests that experts warn could have low accuracy. Testing for viruses is important for early treatment and to help stop their spread. The researchers tested the device using samples of Dengue virus, a mosquito transmitted pathogen that causes Dengue fever and is a threat to people in the tropics. However, the technology can easily be adapted to detect other viruses, like COVID-19.

The device closely matches the accuracy of the gold-standard PCR-based tests but with nearly instantaneous results instead of results that take several days to receive. Its accuracy is also a significant improvement over current rapid antigen tests that the U.S. Food and Drug Administration and U.S. Centers for Disease Control have cautioned could produce inaccurate results if viral loads are low or test instructions are not properly followed. The device works by using nano-scale patterns of gold that reflect back the signature of the virus it is set to detect in a sample of blood. Different viruses can be detected by using different DNA sequences that selectively target specific viruses.

The key to the device’s performance is that it can detect viruses directly from blood samples without the need for sample preparation or purification, thus speeding up the test and improving its accuracy. The researchers confirmed the device’s effectiveness with multiple tests that used different virus concentration levels and solution environments, including those with the presence of non-target virus biomarkers. The next steps for the researchers include adapting the device to detect more viruses.

“The sensitive optical sensor, along with the rapid fabrication approach used in this work, promises the translation of this promising technology to any virus detection including COVID-19 and its mutations with high degree of specificity and accuracy,” said study co-author Debashis Chanda, a professor in UCF’s NanoScience Technology Center. “Here, we demonstrated a credible technique which combines PCR-like genetic coding and optics on a chip for accurate virus detection directly from blood.”

“Although there have been previous optical biosensing demonstration in human serum, they still require off-line complex and dedicated sample preparation performed by skilled personnel — a commodity not available in typical point of care applications,” said Abraham Vazquez-Guardado, the study’s lead author and a postdoctoral fellow at Northwestern University who worked on the research as a doctoral student in Chanda’s lab. “This work demonstrated for the first time an integrated device which separated plasma from the blood and detects the target virus without any pre-processing with potential for near future practical usages.”

Related Links:
University of Central Florida 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.